Management of Dyslipidemia

Access Activity

Overview / Abstract:

Dyslipidemia is one of the major risk factors for coronary artery disease, stroke, and peripheral vascular disease. Strategies for primary and secondary prevention have been developed and published by panels of experts and are intended to serve as guidelines for management of patients at various levels of risk for cardiovascular disease. This course reviews the guidelines for diagnosis and pharmacologic management of dyslipidemia in general and at-risk populations. Complex case studies are the basis for applying the current guidelines to the pharmacologic management of patients.

Learning Objectives:

1. Describe the type of evidence upon which the 2013 ACC/AHA Blood Cholesterol guidelines were based;
2. List the 4 statin benefit groups based on ASCVD risk for secondary and primary prevention;
3. State the populations for whom moderate intensity and high intensity statin therapy are recommended;
4. List the routine monitoring parameters for therapeutic efficacy and toxicity for statin therapy;
5. Given a patient case, recommend an appropriate drug therapy regimen to reduce the risk of ASCVD events; and
6. List the patient populations from whom PSCK9 agents might be considered.

UAN: 0025-0000-15-171-H04-P


Nov 12, 2018


Pharmacy CPE


Online, Webinar / Webcast / Video



Credits / Hours

2.0 Credit Hours



Presenters / Authors / Faculty

David S. Roffman, PharmD, BCPS/Cardiology, Professor, University of Maryland School of Pharmacy

Activity Specialities / Related Topics

Dyslipidemia / Cholesterol

Sponsors / Supporters / Grant Providers

This course is sponsored in part by an educational grant from the Maryland Department of Health and Mental Hygiene and the Institute for a Healthiest Maryland.

Keywords / Search Terms

University of Maryland School of Pharmacy: CIPS Knowledge Enterprise CIPS, Knowledge Enterprise, Dyslipidemia, coronary artery disease, stroke, peripheral vascular disease, primary prevention, secondary prevention, cardiovascular disease, pharmacologic management of patients,

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.